adoptive T lymphocyte therapy (Shenzhen Ruipuxun Academy for Stem Cell & Regenerative Medicine)

N/A

Report date: 2025/03/14 16:44:00

Base Information

Drug Nameadoptive T lymphocyte therapy (Shenzhen Ruipuxun Academy for Stem Cell & Regenerative Medicine)
Drug Alias NameHBV specific CTL therapy (Shenzhen Ruipuxun Academy for Stem Cell & Regenerative Medicine)adoptive T lymphocyte therapy (Shenzhen Ruipuxun Academy)HBV therapy (Shenzhen Ruipuxun Academy for Stem Cell & Regenerative Medicine)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsHepatitis B
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesShenzhen Ripson Institute Of Stem Cell Regenerative Medicine
China Registration ClassN/A

Develop Information

Active CompaniesShenzhen Ripson Institute Of Stem Cell Regenerative Medicine
Inactive CompaniesN/A
Active IndicationsHepatitis B
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A